Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04101682 · ClinicalTrials.gov registry record · Early Phase 1
Continuous Vs Single Shot Block After ACL
A Early Phase 1 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT04101682 is a Early Phase 1 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 9 participants.
The verdict
NCT04101682, a Early Phase 1 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The investigators will be randomizing patients to either receive an adductor canal block in the operating room postoperatively as single shot of 20-30cc bupivacaine or to have a catheter inserted into the adductor canal which will be attached up to a continuous infusion pump of bupivacaine that will have a set flow rate over the next couple days. The investigators' hypothesis is that patients will have better pain control, sleep, and decreased opioid consumption with the use of a continuous infusion pump
Interventions
- DRUG Bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2022-05-17 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04101682
The ClinicalTrials.gov registry entry for NCT04101682 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupivacaine is the first listed.
NCT04101682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04101682 about?
NCT04101682 is a clinical study titled "Continuous Vs Single Shot Block After ACL". The investigators will be randomizing patients to either receive an adductor canal block in the operating room postoperatively as single shot of 20-30cc bupivacaine or to have a catheter inserted into the adductor canal which will be attached up to a continuous infusion pump of bupivacaine that will...
What is the current status of trial NCT04101682?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2020-09-25. Estimated completion is 2022-05-17.
What interventions are being tested in trial NCT04101682?
The interventions under investigation include: Bupivacaine (DRUG).
Who is sponsoring clinical trial NCT04101682?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.